ClinicalTrials.gov
ClinicalTrials.gov Menu

Anti-Aggregative Therapy and Laser Iridectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00426400
Recruitment Status : Unknown
Verified January 2007 by Sheba Medical Center.
Recruitment status was:  Recruiting
First Posted : January 24, 2007
Last Update Posted : January 24, 2007
Sponsor:
Information provided by:
Sheba Medical Center

Brief Summary:
Our study investigates the effect of anti-aggregative treatment on success and complications of laser iridectomy. The study includes patients scheduled for laser iridectomy due to narrow angles.Patients will undergo first laser treatment with the anti-aggregative treatment and will scheduled for next lase in the other eye after discontinuing the anti-aggregative treatment. The patients will be followed-up for 3 months.

Condition or disease Intervention/treatment Phase
Eyes With Narrow Angle Drug: The cessation of anti-aggregative treatment for 10 days Phase 4

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : March 2006




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with narrow angle that need laser iridectomy and take anti- aggregative treatment
  • over 20 years old
  • patients who can stop their anti-aggregative treatment for 10 days

Exclusion Criteria:

  • under coumadin treatment
  • post ocular surgeries

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00426400


Contacts
Contact: Hani Levkovitch-Verbin, MD Hani.Verbin@ sheba.health.gov.il

Locations
Israel
Goldschleger Eye Institute Recruiting
Tel-Hashomer, Israel
Contact: Hani Levkovitch-Verbin, MD       halevko@hotmail.com   
Principal Investigator: Hani Levkovitch-Verbin, MD         
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Hani Levkovitch-Verbin, MD Goldscheleger Eye Institute, Sheba Medical Center

ClinicalTrials.gov Identifier: NCT00426400     History of Changes
Other Study ID Numbers: SHEBA-05-3876-HLV-CTIL
First Posted: January 24, 2007    Key Record Dates
Last Update Posted: January 24, 2007
Last Verified: January 2007